ICCC
ImmuCell Corporation
NASDAQ · Healthcare · Biotechnology · US
$9.90
−1.00%Margins
Gross margin
40.3%
EBITDA margin
11.5%
EBIT margin
12.6%
Net margin
2.6%
FCF margin
13.7%
2.5%
Return on equity
1.7%
Return on assets
8.8%
Return on invested capital
0.68x
Asset turnover
$5.9M
Cash from operations
$0.98
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026